Literature DB >> 12050367

Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment).

Pheroze Joshi1, Vinayaka R Prasad.   

Abstract

RNA aptamers derived by SELEX (systematic evolution of ligands by exponential enrichment) and specific for human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) bind at the template-primer cleft with high affinity and inhibit its activity. In order to determine the potential of such template analog RT inhibitors (TRTIs) to inhibit HIV-1 replication, 10 aptamers were expressed with flanking, self-cleaving ribozymes to generate aptamer RNA transcripts with minimal flanking sequences. From these, six aptamers (70.8,13, 70.15, 80.55,65, 70.28, 70.28t34, and 1.1) were selected based on binding constants (K(d)) and the degree of inhibition of RT in vitro (50% inhibitory concentration [IC(50)]). These six aptamers were each stably expressed in 293T cells followed by transfection of a molecular clone of HIV(R3B). Analysis of the virion particles revealed that the aptamers were encapsidated into the virions released and that the packaging of the viral genomic RNA or the cognate primer, tRNA(Lys)(3), was apparently unaffected. Infectivity of virions produced from 293T cell lines expressing the aptamers, as measured by infecting LuSIV reporter cells, was reduced by 90 to 99.5% compared to virions released from cells not expressing any aptamers. PCR analysis of newly made viral DNA upon infection with virions containing any of the three aptamers with the strongest binding affinities (70.8,13, 70.15, and 80.55,65) showed that all three were able to form the minus-strand strong-stop DNA. However, virions with the aptamers 70.8 and 70.15 were defective for first-strand transfer, suggesting an early block in viral reverse transcription. Jurkat T cells expressing each of the three aptamers, when infected with HIV(R3B), completely blocked the spread of HIV in culture. We found that the replication of nucleoside analog RT inhibitor-, nonnucleoside analog RT inhibitor-, and protease inhibitor-resistant viruses was strongly suppressed by the three aptamers. In addition, some of the HIV subtypes were severely inhibited (subtypes A, B, D, E, and F), while others were either moderately inhibited (subtypes C and O) or were naturally resistant to inhibition (chimeric A/D subtype). As virion-encapsidated TRTIs can predispose virions for inhibition immediately upon entry, they should prove to be efficacious agents in gene therapy approaches for AIDS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12050367      PMCID: PMC136251          DOI: 10.1128/jvi.76.13.6545-6557.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Effects of mutations in Pr160gag-pol upon tRNA(Lys3) and Pr160gag-plo incorporation into HIV-1.

Authors:  J Mak; A Khorchid; Q Cao; Y Huang; I Lowy; M A Parniak; V R Prasad; M A Wainberg; L Kleiman
Journal:  J Mol Biol       Date:  1997-01-31       Impact factor: 5.469

2.  Inhibition of HIV-1 replication using a mutated tRNALys-3 primer.

Authors:  Y Lu; V Planelles; X Li; C Palaniappan; B Day; P Challita-Eid; R Amado; D Stephens; D B Kohn; A Bakker; P Fay; R A Bambara; J D Rosenblatt
Journal:  J Biol Chem       Date:  1997-06-06       Impact factor: 5.157

3.  Polyamide nucleic acid targeted to the primer binding site of the HIV-1 RNA genome blocks in vitro HIV-1 reverse transcription.

Authors:  R Lee; N Kaushik; M J Modak; R Vinayak; V N Pandey
Journal:  Biochemistry       Date:  1998-01-20       Impact factor: 3.162

4.  Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection.

Authors:  K Mori; Y Yasutomi; S Sawada; F Villinger; K Sugama; B Rosenwith; J L Heeney; K Uberla; S Yamazaki; A A Ansari; H Rübsamen-Waigmann
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

5.  Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals.

Authors:  U Ranga; C Woffendin; S Verma; L Xu; C H June; D K Bishop; G J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

6.  Bent pseudoknots and novel RNA inhibitors of type 1 human immunodeficiency virus (HIV-1) reverse transcriptase.

Authors:  D H Burke; L Scates; K Andrews; L Gold
Journal:  J Mol Biol       Date:  1996-12-13       Impact factor: 5.469

7.  LuSIV cells: a reporter cell line for the detection and quantitation of a single cycle of HIV and SIV replication.

Authors:  J W Roos; M F Maughan; Z Liao; J E Hildreth; J E Clements
Journal:  Virology       Date:  2000-08-01       Impact factor: 3.616

8.  Phosphorothioate oligonucleotides derived from human immunodeficiency virus type 1 (HIV-1) primer tRNALys3 are strong inhibitors of HIV-1 reverse transcriptase and arrest viral replication in infected cells.

Authors:  R El Dirani-Diab; L Sarih-Cottin; B Delord; B Dumon; S Moreau; J J Toulme; H Fleury; S Litvak
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

9.  The structure of HIV-1 reverse transcriptase complexed with an RNA pseudoknot inhibitor.

Authors:  J Jaeger; T Restle; T A Steitz
Journal:  EMBO J       Date:  1998-08-03       Impact factor: 11.598

10.  Triple ribozyme-mediated down-regulation of the retinoblastoma gene.

Authors:  C M Benedict; W Pan; S E Loy; G A Clawson
Journal:  Carcinogenesis       Date:  1998-07       Impact factor: 4.944

View more
  31 in total

1.  Inhibition of HIV-1 reverse transcriptase by RNA aptamers in Escherichia coli.

Authors:  David G Nickens; James T Patterson; Donald H Burke
Journal:  RNA       Date:  2003-09       Impact factor: 4.942

2.  Structure of HIV-1 reverse transcriptase bound to a novel 38-mer hairpin template-primer DNA aptamer.

Authors:  Matthew T Miller; Steve Tuske; Kalyan Das; Jeffrey J DeStefano; Eddy Arnold
Journal:  Protein Sci       Date:  2015-09-18       Impact factor: 6.725

3.  Tighter binding of HIV reverse transcriptase to RNA-DNA versus DNA-DNA results mostly from interactions in the polymerase domain and requires just a small stretch of RNA-DNA.

Authors:  William P Bohlayer; Jeffrey J DeStefano
Journal:  Biochemistry       Date:  2006-06-20       Impact factor: 3.162

4.  Novel aptamer inhibitors of human immunodeficiency virus reverse transcriptase.

Authors:  Jeffrey J DeStefano; Gauri R Nair
Journal:  Oligonucleotides       Date:  2008-06

Review 5.  Aptamers in HIV research diagnosis and therapy.

Authors:  Jyoti Bala; Srinivasan Chinnapaiyan; Rajib Kumar Dutta; Hoshang Unwalla
Journal:  RNA Biol       Date:  2018-02-12       Impact factor: 4.652

6.  Aptamers that preferentially bind type IVB pili and inhibit human monocytic-cell invasion by Salmonella enterica serovar typhi.

Authors:  Qin Pan; Xiao-Lian Zhang; Hong-Yan Wu; Pan-Wen He; Fubin Wang; Ming-Sheng Zhang; Jian-Ming Hu; Bing Xia; Jianguo Wu
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

7.  RNA aptamers directed to human immunodeficiency virus type 1 Gag polyprotein bind to the matrix and nucleocapsid domains and inhibit virus production.

Authors:  Dhivya Ramalingam; Sonald Duclair; Siddhartha A K Datta; Andrew Ellington; Alan Rein; Vinayaka R Prasad
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

8.  Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers.

Authors:  Daniel M Held; Jay D Kissel; Sarah J Thacker; Daniel Michalowski; Dayal Saran; Jianfei Ji; Richard W Hardy; John J Rossi; Donald H Burke
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

Review 9.  Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1.

Authors:  Jiehua Zhou; John J Rossi
Journal:  BioDrugs       Date:  2012-12-01       Impact factor: 5.807

10.  Novel bimodular DNA aptamers with guanosine quadruplexes inhibit phylogenetically diverse HIV-1 reverse transcriptases.

Authors:  Daniel Michalowski; Rebecca Chitima-Matsiga; Daniel M Held; Donald H Burke
Journal:  Nucleic Acids Res       Date:  2008-11-07       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.